Biota Pharmaceuticals, Inc.

Q: Jun 30 2026

Q: Mar 31 2026

FY: Dec 31 2025

FY: Dec 31 2025

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Other Events

Other Events

Results of Operations and Financial Condition

Other Events

Submission of Matters to a Vote of Security Holders

Other Events

Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement

Other Events

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Other Events

Entry into a Material Definitive Agreement

Results of Operations and Financial Condition

Termination of a Material Definitive Agreement

Results of Operations and Financial Condition

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Other Events

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Prospectus Supplement for Primary Offering

Amended Initial Registration Statement

Notice of Effectiveness

Registration (IPO) statement under Securities Act of 1933

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Notification of removal from listing and/or registration on a national securities exchange

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Prospectus Supplement for Primary Offering

Notice of Effectiveness

Registration statement under Securities Act of 1933

Additional Information for Proxy Statement/ Votes

Additional proxy soliciting materials filed by a non-management party

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional proxy soliciting materials filed by a non-management party

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional proxy soliciting materials filed by a non-management party

Additional Information for Proxy Statement/ Votes

Additional proxy soliciting materials filed by a non-management party

Additional Information for Proxy Statement/ Votes

No description available

Additional Information for Proxy Statement/ Votes

No description available

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Finney Kevin

Wheadon David E.

Watson W. Mark

HERON ELAINE J

BREITMEYER JAMES B

Watson W. Mark

Grasman Jeroen Nicolaas

BREITMEYER JAMES B

BREITMEYER JAMES B

Cummings James F.

Tucker Sean

Lo Steven

Berg Edward B

Tucker Sean

Cummings James F.

Tucker Sean

Cummings James F.

Lo Steven

Berg Edward B

Berg Edward B

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

No description available

No description available

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC